EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeted demethylation of the BRD7 promoter based on CRISPR/dCas9 system inhibits the malignant progression of nasopharyngeal carcinoma

Jianxia Wei, Yumei Duan, Changning Xue, Lemei Zheng, Qingqing Wei, Zubing Wu, Huizhen Xin, Ting Zeng, Hongyu Deng, Songqing Fan, Wei Xiong, Zhaoyang Zeng und 2 weitere

Clinical and Translational Medicine · 2026

DOI: 10.1002/ctm2.70583 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2026. Verfasst von Jianxia Wei und 13 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya Sc…. Hauptthemen laut MEDLINE: Nasopharyngeal Carcinoma, Promoter Regions, Genetic, Chromosomal Proteins, Non-Histone, Nasopharyngeal Neoplasms. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Natural Science Foundation of China, the Human Provincial key Research and Development Program, the Free Exploration Program of Central South University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

BRD7 has been confirmed to be lowly expressed in nasopharyngeal carcinoma (NPC) tissues and exerts tumour suppressive roles. However, the molecular mechanism of the downregulation of BRD7 expression and whether the strategy of activating BRD7 expression plays anti‐tumour effects still needs to be clarified.

Methods

Methylation‐specific polymerase chain reaction (PCR) was used to identify the methylation levels of BRD7 promoter. In vitro experiments were used to evaluate the effects of BRD7‐targeted demethylation system on the malignant progression of NPC cells. Chromatin immunoprecipitation (ChIP)‐qPCR experiment was employed to examine the regulatory mechanisms underlying the demethylation system. Xenograft tumour models were used to assess impact of this demethylation system on tumour growth in vivo and the anti‐tumour effects of the lentivirus‐mediated demethylation system in NPC.

Results

There was hypermethylation modification in BRD7 promoter, which was negatively correlated with BRD7 expression. Next, we constructed a LentiCRISPRv2/dCas9‐TET1CD‐sgRNAs system targeting specific methylation sites of BRD7 promoter based on five sgRNAs, and confirmed that all five sgRNA‐guided CRISPR/dCas9 systems could activate BRD7 and inhibit cell proliferation to varying degrees, among which sgRNA2&sgRNA5 were the most significant. Further, we constructed NPC cell lines stably transfected with LentiCRISPRv2/dCas9‐TET1CD‐sgRNA2&5, and confirmed that both sgRNA2&sgRNA5 could promote the transcriptional activation by reducing its methylation, and inhibit the cell proliferation, migration, invasion and tumour growth in vivo of NPC, and the combination of them has a more significant demethylation, transcriptional activation and anti‐tumour effect. In addition, BRD7 had hypermethylation modification in its promoter and decreased expression in NPC tissues, and both of them were negatively correlated, making it a potential diagnostic marker for NPC diagnosis.

Conclusions

The hypermethylation modification of BRD7 is an important mechanism leading to the inactivation of BRD7, and targeting demethylation of BRD7 inhibits the malignant progression of NPC, which might be a promising targeted therapeutic approach for treating NPC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nasopharyngeal CarcinomaPromoter Regions, GeneticChromosomal Proteins, Non-HistoneNasopharyngeal NeoplasmsCRISPR-Cas SystemsHumansBromodomain Containing ProteinsAnimalsMiceCell Line, TumorDisease ProgressionDNA MethylationMice, NudeFemaleCell ProliferationDNA Demethylation

Stichwörter der Autor:innen

BRD7CRISPR/dCas9demethylationmalignant progressionnasopharyngeal carcinoma

Substanzen

Bromodomain Containing ProteinsBRD7 protein, humanChromosomal Proteins, Non-Histone

Autor:innen und Institutionen

  • NHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
  • Cancer Research Institute and Xiangya School of Basic Medical Sciences, Central South University, Changsha, China.
  • The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Central South University, Changsha, China.
  • Department of Pathology, the Xiangya Hospital, Central South University, Changsha, China.
  • Department of Pathology, the Second Xiangya Hospital, Central South University, Changsha, China.

Förderung

  • the National Natural Science Foundation of China
  • the Human Provincial key Research and Development Program
  • the Free Exploration Program of Central South University
  • the scientific research plan project of Hunan Provincial Health Commission
  • the program of Introducing Talents of Discipline to Universities

Zitieren

APA

Wei, J., Duan, Y., Xue, C., Zheng, L., Wei, Q., Wu, Z., Xin, H., Zeng, T., Deng, H., Fan, S., Xiong, W., Zeng, Z., Li, M., & Zhou, M. (2026). Targeted demethylation of the BRD7 promoter based on CRISPR/dCas9 system inhibits the malignant progression of nasopharyngeal carcinoma. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70583

Vancouver

Wei J, Duan Y, Xue C, Zheng L, Wei Q, Wu Z, et al. Targeted demethylation of the BRD7 promoter based on CRISPR/dCas9 system inhibits the malignant progression of nasopharyngeal carcinoma. Clinical and Translational Medicine. 2026. doi:10.1002/ctm2.70583

BibTeX
@article{Wei2026,
  author = {Wei, Jianxia and Duan, Yumei and Xue, Changning and Zheng, Lemei and Wei, Qingqing and Wu, Zubing and Xin, Huizhen and Zeng, Ting and Deng, Hongyu and Fan, Songqing and Xiong, Wei and Zeng, Zhaoyang and Li, Mengna and Zhou, Ming},
  title = {Targeted demethylation of the BRD7 promoter based on CRISPR/dCas9 system inhibits the malignant progression of nasopharyngeal carcinoma},
  journal = {Clinical and Translational Medicine},
  year = {2026},
  doi = {10.1002/ctm2.70583}
}
Kostenlos starten →